Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse
Brenda Cooper(University Hospitals Cleveland Medical Center), Glen Raffel(University of Massachusetts Chan Medical School), Divya Koura(University of California San Diego), Nirali N. Shah(National Institutes of Health), Ali Lacy, Hyung C. Suh(Science Applications International Corporation (United States)), Darren Stanizzi(Dana-Farber Cancer Institute), Karen Kuhn, Nadia M. Bambace(Hôpital Maisonneuve-Rosemont), John F. DiPersio(Washington University in St. Louis), Jennifer Whangbo(Boston Children's Hospital), Sritama Nath(University of North Carolina at Charlotte), Guenther Koehne(Baptist Hospital of Miami), Christina Cho(Cornell University), Léa Bernard(Hôpital Maisonneuve-Rosemont), Melissa M. Lee‐Sundlov(Versiti Blood Center of Wisconsin), Christopher A. Slapak(Eli Lilly (United States)), Roland B. Walter(Rafael Advanced Defense Systems (Israel))
Cited by 7
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
|Pharmacology & Therapeutics|2016|921
MUC1: a multifaceted oncoprotein with a key role in cancer progression
|Trends in Molecular Medicine|2014|854
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783